Double Bond Pharmaceutical Board
Double Bond Pharmaceutical products are targeted to markets with unmet needs in order to ensure high up-side potential of the company and unique investment possibilities for the partners. Double Bond Pharmaceutical is also open for collaboration with Pharmaceutical companies for the development of novel treatments as well as the improvement of existing medicinal products.
Board of Directors
Per Stålhandske – Chairman
Per Stålhandske, born 1954, Chairman and Member of the Board in Double Bond Pharmaceutical International AB since April 2015. Per has a PhD in Medical Genetics from Uppsala University and has been involved in commercializing academic innovations. Per is the Managing Director of cSens AB and has also served as Quality Assurance Manager at Oasmia Pharmaceutical AB. He has extensive experience in GMP and intellectual property rights.
Lars Thomander, born 1947, Member of the Board in Double Bond Pharmaceutical International AB since April 2015. Doctor Lars Thomander is an Otorhinolaryngologist and Associate Professor at Uppsala University. After 12 years at the Uppsala University Hospital he started as a Nordic Medical Director at Eli Lilly followed by several other Medical Director positions in Europe. Year 2000 back in Sweden he founded HLT Consult Ltd, consulting in drug development as the main focus. 2009 -2013 he served as Medical Director at Abbott and Abbvie in Stockholm. He is former President of the Swedish Society for Pharmaceutical Medicine and a Board Member of the Foundation for Pharmaceutical Medicine, and Chairman of CaptiGel since 2014.
Sergey Yanitsky, born 1965, Member of the Board in Double Bond Pharmaceutical International AB since April 2015. Sergey´s expertise in the Pharmaceutical Industry lies in manufacturing, marketing and international distribution of pharmaceuticals. He is the founder and CEO of MedInter which is a vertically integrated pharmaceutical company started in 2001.
Igor Lokot, born 1972, Member of the Board in Double Bond Pharmaceutical International AB since April 2015. Igor has a PhD in Bio-organic Chemistry and a wide experience in drug development. Igor is one of the founders of the pharmaceutical company Oasmia Pharmaceutical AB which is listed on NASDAQ Stockholm.